Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharma is supported by a de-risked RNAi platform that has now demonstrated compelling, commercially relevant efficacy in severe hypertriglyceridemia, with plozasiran producing 79% and 81% median triglyceride reductions in SHASTA-3 and SHASTA-4 versus about 27% for placebo, while 91% to 93% of treated patients were below 500 mg/dL and 52% to 55% were below 150 mg/dL at Month 12. The investment case is further strengthened by clinically meaningful acute pancreatitis reduction, including a 283-day median time to first AP event versus 182 days on placebo, a 78% reduction in AP events in the broad sHTG population, and a 100% reduction in the highest-risk subgroup with an NNT of 3, all alongside a clean safety profile with no new safety signals and no clinically meaningful hepatic fat accumulation. Fundamentally, the company also appears well positioned for value creation because management is advancing toward a 2026 sNDA filing and a 2027 launch with Priority Review Voucher support, while targeting a large addressable market of more than 3 million U.S. patients at or above 500 mg/dL, roughly 1 million high-risk patients, and a broader cardiometabolic franchise that could be expanded by an already validated commercial launch and a pipeline with multiple shots on goal.

Arrowhead Pharma is burdened by a risk profile that remains unusually high despite encouraging clinical efficacy, because much of its valuation depends on forward assumptions, probability-weighted pipeline success, and revenue that is still distant and uncertain. The company faces substantial dilution and financing risk, with estimated annual equity raises of $350 million in 2027E and continued cash burn that may force additional capital raises on unfavorable terms, while competitive intensity in RNA medicines, uncertain IP protection, and commercialization/reimbursement challenges could erode the value of even successful programs. Although plozasiran has shown strong triglyceride reductions of 79% to 81% and a 78% reduction in acute pancreatitis events, the data are not directly comparable to rivals, superiority is unproven, and the broader sHTG opportunity may be contested after Redemplo’s November 2025 FCS launch and its entry at least a year behind Tryngolza.